Back

Watch Compare

Silexion Therapeutics Corp

Data quality: 83%

Also listed as SLXNW NASDAQ

SLXN

NASDAQ Manufacturing Chemicals

$1.00

▼ $0.02 (-1.96%)

6 months return

—

Momentum

Neutral

ROE

-335.69%

Growth

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Quality

Return on Equity

-335.69%

Below sector avg (-54.47%)

ROIC-147.32%

Net MarginN/A

Op. MarginN/A

Safety

Debt / Equity

N/A

Current Ratio3.97

Interest CoverageN/A

Valuation

PE (TTM)

-0.31

Above sector avg (-1.50)

P/B Ratio0.53

EV/EBITDAN/A

Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -10.83 M

Price History

Financial Trends

Analyst Price Target

2 analysts

Strong Buy

+500.0%

upside to target

Current

$1.00

Consensus Target

$6.00

Low

$6.00

High

Forecast

Forward EPS

-$2.87

Est. Revenue

0.0

Earnings Surprises

EPS

Reported Estimate Forecast

Next: Q1 2026 · EPS Est: -$1.29 · Rev Est: 0.0

	Q32025	Q42025	Q1 '26	Q2 '26
Reported	-$2.88	—	—	—
Estimate	-$3.40	-$1.12	-$1.29	-$1.31
Surprise	+15.29%	—	—	—

Growth

Rev 5Y: N/A · Earnings 1Y: N/A

Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A

Profitability

ROE: -335.69% · Net Margin: N/A

Revenue (TTM)	N/A	Net Income (TTM)	-11.91 M
ROE	-335.69%	ROA	-136.83%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-10.83 M
ROIC	-147.32%	FCF Growth (3Y)	N/A

Safety

D/E: N/A · Current: 3.97

Debt / Equity	N/A	Current Ratio	3.97
Interest Coverage	N/A	Asset Turnover	N/A
Working Capital	8.27 M	Tangible Book Value	6.98 M

Dividends

Yield: N/A · Payout: N/A

Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A

Valuation

P/E: -0.31 · EV/EBITDA: N/A

P/E Ratio	-0.31	Forward P/E	N/A
P/B Ratio	0.53	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-292.87%
Market Cap	3.70 M	Enterprise Value	-5.55 M

Per Share

EPS: 8.96 · FCF/Share: -3.25

EPS (Diluted TTM)	8.96	Revenue / Share	N/A
FCF / Share	-3.25	OCF / Share	-3.25
EPS CAGR (1Y)	-66.01%	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A

Efficiency

FCF Conv: 90.90% · CapEx/Rev: N/A

CapEx / Revenue	N/A	FCF Conversion	90.90%
SBC-Adj. FCF	-10.99 M	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2025	FY2024
Revenue	—	—
Net Income	-11.91 M	-16.52 M
EPS (Diluted)	8.96	26.36
Gross Profit	—	—
Operating Income	-11.63 M	-12.57 M
EBITDA	—	—
R&D Expenses	7.14 M	5.82 M
SG&A Expenses	—	—
D&A	—	—
Interest Expense	—	—
Income Tax	3,000.0	10,000.0

Balance Sheet

Annual, most recent first

Metric	FY2025	FY2024
Total Assets	7.22 M	2.86 M
Total Liabilities	4.61 M	6.85 M
Shareholders' Equity	2.60 M	-3.99 M
Total Debt	—	—
Cash & Equivalents	5.99 M	1.19 M
Current Assets	6.64 M	2.25 M
Current Liabilities	2.76 M	3.52 M

Peer Comparison

vs Manufacturing sector median (1605 peers)

Metric	Stock	Sector Median
P/E	-0.3	-1.5
P/B	0.5	1.6
ROE %	-335.7	-54.5
Net Margin %	—	-41.5
Rev Growth 5Y %	—	1.8
D/E	—	0.3